Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Huh, Hyuk | - |
dc.contributor.author | Kim, Yong Soo | - |
dc.contributor.author | Chung, Wookyung | - |
dc.contributor.author | Kim, Yong Lim | - |
dc.contributor.author | Kim, Yaerim | - |
dc.contributor.author | Han, Seungyeup | - |
dc.contributor.author | Jung, Yeonsoon | - |
dc.contributor.author | Na, Ki Young | - |
dc.contributor.author | Lee, Kyu Beck | - |
dc.contributor.author | Oh, Yun Kyu | - |
dc.contributor.author | Park, Hyeong Cheon | - |
dc.contributor.author | Han, Seung Hyeok | - |
dc.contributor.author | Yoo, Tae Hyun | - |
dc.contributor.author | Kim, Yeong Hoon | - |
dc.contributor.author | Kim, Soo Wan | - |
dc.contributor.author | Lee, Kang Wook | - |
dc.contributor.author | Park, Hayne Cho | - |
dc.contributor.author | Kim, Sung Gyun | - |
dc.contributor.author | Kim, Hyunsuk | - |
dc.contributor.author | Lee, Chang Hwa | - |
dc.contributor.author | Bae, Kyongtae T. | - |
dc.contributor.author | Oh, Kook Hwan | - |
dc.contributor.author | Ahn, Curie | - |
dc.contributor.author | Ryu, Hyun Jin | - |
dc.contributor.author | Kim, Yong Chul | - |
dc.date.accessioned | 2023-05-23T08:41:12Z | - |
dc.date.available | 2023-05-23T08:41:12Z | - |
dc.date.created | 2023-05-23 | - |
dc.date.issued | 2023-03 | - |
dc.identifier.issn | 2211-9132 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87978 | - |
dc.description.abstract | Background: Tolvaptan reduces height-adjusted total kidney volume (htTKV) and renal function decline in autosomal dominant poly -cystic kidney disease (ADPKD). This study was aimed at investigating the efficacy and safety of tolvaptan in Korean patients with ADP-KD during the titration period.Methods: This study is a multicenter, single-arm, open-label phase 4 study. We enrolled 108 patients with ADPKD (age, 19-50 years) with an estimated glomerular filtration rate (eGFR) of >30 mL/min/1.73 m2 and factors defined as indicative of rapid disease progres-sion. After tolvaptan titration, we evaluated efficacy and side effects and assessed factors associated with the effects.Results: After titration for 4 weeks, eGFR and htTKV decreased by 6.4 +/- 7.9 mL/min/1.73 m2 and 16 +/- 45 mL/m, respectively. No se-rious adverse drug reactions were observed during the titration period. The greatest eGFR decline was observed in the first week, with a starting tolvaptan dose of 45 mg. Multivariate linear regression for htTKV decline showed that the greater the change in urine osmo-lality (Uosm), the greater the decrease in htTKV (beta, 0.436; p = 0.009) in the 1D group stratified by the Mayo Clinic image classification. Higher baseline eGFR was related to a higher htTKV reduction rate in the 1E group (beta, -0.642; p = 0.009).Conclusion: We observed short-term effects and safety during the tolvaptan titration period. The decline of htTKV can be predicted as a short-term effect of tolvaptan by observing Uosm changes from baseline to end of titration in 1D and baseline eGFR in 1E groups. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC NEPHROLOGY | - |
dc.relation.isPartOf | KIDNEY RESEARCH AND CLINICAL PRACTICE | - |
dc.title | Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000974142000005 | - |
dc.identifier.doi | 10.23876/j.krcp.22.024 | - |
dc.identifier.bibliographicCitation | KIDNEY RESEARCH AND CLINICAL PRACTICE, v.42, no.2, pp.216 - 228 | - |
dc.identifier.kciid | ART002981578 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85164260192 | - |
dc.citation.endPage | 228 | - |
dc.citation.startPage | 216 | - |
dc.citation.title | KIDNEY RESEARCH AND CLINICAL PRACTICE | - |
dc.citation.volume | 42 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Chung, Wookyung | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Clinical trial phase IV | - |
dc.subject.keywordAuthor | Polycystic kidney autosomal dominant | - |
dc.subject.keywordAuthor | Tolvaptan | - |
dc.subject.keywordPlus | VOLUME | - |
dc.subject.keywordPlus | ADPKD | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.